新景智源与百济神州签署授权协议,以支持百济神州开发下一代细胞治疗药物

投资界综合
03 Jun

北京时间2025年6月3日,新景智源生物科技(苏州)有限公司(以下简称新景智源),一家专注于实体肿瘤TCR-T免疫细胞治疗药物的研发企业,宣布与百济神州签署了非*许可协议, 将向百济神州授权一项公司自主研发的抗原特异性的TCR分子的权益,用于百济神州开发基于iPSC平台的下一代通用型细胞治疗药物。根据协议,新景智源将获得首付款,并在未来基于所授权TCR分子开展的合作研究项目中,按研发进展、注册进展...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10